Press Release

CREATIVE DIAGNOSTICS LAUNCHES NEW P53 AND TP53 ANTIBODIES FOR CANCER RESEARCH



Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

FOR IMMEDIATE RELEASE

23/01/2024

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development and progression.

P53 is a potent tumor suppressor encoded by the TP53 gene on human chromosome 17. As a transcription factor, P53 coordinates the expression of target genes to promote cell cycle arrest, apoptosis, and DNA repair. In addition, P53 exerts antiproliferative effects through transcription-independent mechanisms.

Mutations in the TP53 gene reduce the tumor suppressor activity of the encoded P53 protein. They are present in approximately half of all human malignancies, including breast, colorectal, lung, liver, prostate, bladder and skin cancers. Cancer-associated TP53 gene mutations are primarily missense mutations, which result in the substitution of a single amino acid. Although hundreds of different P53 mutations have been documented, some are particularly common and are known as hotspot mutations, such as R175, G245, R248, R249, R273, and R282.

P53 is involved in a number of pathways that affect oncogenic biological processes, including cell proliferation, G2/M phase, and apoptosis. Under excessive oncogenic stress, activation of p53 induces senescence and cell cycle arrest, which is an important regulatory mechanism for tumor suppression. P53 tumor suppressor function may also act through recruitment or regulation of other oncogenes, for example, p53 directly binds to the promoter of ITIH5 in melanoma cells and promotes transcription of ITIH5, which inhibits proliferation and migration of melanoma cells.

Several studies have shown that transfection of cancer cells with plasmids expressing wild-type P53 induces apoptosis and/or growth arrest. To date, several clinical trials have been completed using viral and non-viral vectors to deliver the P53 gene either alone or in combination with other therapeutic agents.

Creative Diagnostics has developed a panel of high-quality materials to assist customers worldwide in their research into the functions, oncogenic pathways, and potential treatment of P53 and TP 53, including monoclonal antibodies, polyclonal antibodies, phospho-specific antibodies, mutation-specific antibodies and acetyl-specific antibodies.

These versatile antibodies offer a wide range of applications, targeting multiple species and validated for diverse research needs. Not only can they distinguish between wild type and mutant protein types, covering a wide range of mutation sites, but they can also detect post-translational modifications at different sites (including methylation, phosphorylation, and amidation). They are also available with a variety of labels that are compatible with different detection methods and exhibit high specificity and minimal batch-to-batch variation. This combination of broad applicability, precision, and cost effectiveness makes these antibodies a valuable tool for researchers.

Creative Diagnostics offers a wide range of quality P53 and TP53 antibodies to support customers’ research needs. For more information on the new antibodies, please visit https://www.creative-diagnostics.com/p53-and-tp53-critical-objective-in-cancer-research.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.

Tags:
P53 and Tp53 Antibodies  |  Creative Diagnostics  |  

---

Organisation Profile:
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to be a trusted source for all your assay development and manufacturing needs.






Press release contact details for Creative Diagnostics

NameCreative Diagnostics
Tel
Fax
Email
Websitehttps://www.creative-diagnostics.com/
OrganisationCreative Diagnostics
Address
Town
County0
Postcode11967




Other press releases from Creative Diagnostics

Creative Diagnostics Launches HPV L1 Antibodies for Neutralization and Vaccine Development
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics Introduces Virus Yield Reduction Assay Service
Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers
Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research
Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research
Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics Launches Antimicrobial Synergy Testing Services
Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications
Creative Diagnostics Launches Checkerboard Assay Services
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing Read more: https://www.digitaljournal.com/pr/news/getnews/creative-diagnostics-announces-new-mbc-assay-for-antibacterial-testing#ixzz8KcL65cji
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing
Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues
Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness
Creative Diagnostics Launches New P53 and TP53 Antibodies for Cancer Research
Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety
Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens
Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy
Citrinin Test Reagents for Food Safety
Creative Diagnostics Announces Novel Agar Gel Precipitin Tests for Viral Antigen Detection
Creative Diagnostics Introduces Cutting-Edge Anti-AAV Antibody ELISA Kits for Gene Therapy Research
Creative Diagnostics Announces the Launch of Its Highly Sensitive Kanamycin ELISA Kit for Precise Antibiotic Detection
Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development
Creative Diagnostics Announces Comprehensive Vomitoxin Test Reagents for Food Safety Applications

Disclaimer:
Issuers of the press releases are solely responsible for the content of their press releases. Connect2business.co.uk cannot be held liable for the content posted by others to this website.